Losartan potassium-hydrochlorothiazide



Member of Farmavita.Net offers generic EU CTD Dossier of Losartan potassium-hydrochlorothiazide, tablets, 50+12.5/100+25 mg.

Registration is going-on in refrence member state of EU.

Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.

As with all angiotensin II receptor antagonists, losartan is indicated for the treatment of hypertension. Losartan may also delay progression of diabetic nephropathy and is also indicated for the reduction of renal disease progression in patients with type 2 diabetes, hypertension and microalbuminuria (>30 mg/24 hours) or proteinuria (>900 mg/24 hours).

Although angiotensin II receptor antagonists are not usually considered first-line, because of the proven efficacy and lower costs of thiazide diuretics and beta blockers, losartan may be used first-line in patients with increased cardiovascular risk. The LIFE study demonstrated that losartan was significantly superior to atenolol in the primary prevention of adverse cardiovascular events (myocardial infarction or stroke), with a significant reduction in cardiovascular morbidity and mortality for a comparable reduction in blood pressure.

More details at: http://www.rxlist.com/hyzaar-drug.htm.

More details

Name Description
Pharma licensing Out-licensing (offer)

Ad details

Ad ID : 586
Contact Advertiser

Add comment

Related adverts

Phone number

Sorry, you need to register or login first.


Sorry, you need to register or login first.

Contact form

Sorry, you need to register or login first.

What's wrong with this ad?

Sorry, you need to register or login first.

Add to favorites

Sorry, you need to register or login first.